Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Morton Coleman

Showing results (71-80 of 118) with videos related to

Pageof 12
Sort By:
The New England Journal of Medicine|November 5, 2015
Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell LymphomaJia Ruan, Peter Martin, Bijal Shah, et al.
Leukemia & Lymphoma|April 10, 2008
FDG-PET in prediction of splenectomy findings in patients with known or suspected lymphomaSarah C Rutherford, Biree Andemariam, Shibu M Philips, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 21, 2017
Cellular Proliferation by Multiplex Immunohistochemistry Identifies High-Risk Multiple Myeloma in Newly Diagnosed, Treatment-Naive PatientsScott Ely, Peter Forsberg, Ihsane Ouansafi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2009
Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II resultsFranck Morschhauser, John P Leonard, Luis Fayad, et al.
Cancer|December 20, 2005
Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphomaAlan D Dosik, Morton Coleman, Lale Kostakoglu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2010
Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphomaJia Ruan, Peter Martin, Richard R Furman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2005
Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphomaJohn P Leonard, Morton Coleman, Lale Kostakoglu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 3, 2003
Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphomaJohn P Leonard, Morton Coleman, Jamie C Ketas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2014
In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphomaMartin Hutchings, Lale Kostakoglu, Jan Maciej Zaucha, et al.
Ejhaem|February 23, 2023
Zanubrutinib in patients with treatment-naïve or relapsed/refractory Waldenström macroglobulinemia: An expanded-access study of 50 patients in the United StatesJorge J Castillo, Edwin C Kingsley, Mohit Narang, et al.
Pageof 12

Showing results (71-80 of 118) with videos related to

Sort By:
Pageof 12
The New England Journal of Medicine|November 5, 2015
Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell LymphomaJia Ruan, Peter Martin, Bijal Shah, et al.
Leukemia & Lymphoma|April 10, 2008
FDG-PET in prediction of splenectomy findings in patients with known or suspected lymphomaSarah C Rutherford, Biree Andemariam, Shibu M Philips, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 21, 2017
Cellular Proliferation by Multiplex Immunohistochemistry Identifies High-Risk Multiple Myeloma in Newly Diagnosed, Treatment-Naive PatientsScott Ely, Peter Forsberg, Ihsane Ouansafi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2009
Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II resultsFranck Morschhauser, John P Leonard, Luis Fayad, et al.
Cancer|December 20, 2005
Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphomaAlan D Dosik, Morton Coleman, Lale Kostakoglu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2010
Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphomaJia Ruan, Peter Martin, Richard R Furman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2005
Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphomaJohn P Leonard, Morton Coleman, Lale Kostakoglu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 3, 2003
Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphomaJohn P Leonard, Morton Coleman, Jamie C Ketas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2014
In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphomaMartin Hutchings, Lale Kostakoglu, Jan Maciej Zaucha, et al.
Ejhaem|February 23, 2023
Zanubrutinib in patients with treatment-naïve or relapsed/refractory Waldenström macroglobulinemia: An expanded-access study of 50 patients in the United StatesJorge J Castillo, Edwin C Kingsley, Mohit Narang, et al.
Pageof 12